Pharmaceutical Development and Technology最新文献_第10页

Carvedilol microemulsion-loaded oleogel for oral delivery: investigation of in vitro drug release and evaluation of chemical and physical stability. 口服卡维地洛微乳油凝胶：体外释药研究及化学和物理稳定性评价。

IF 2.5 4区医学

Pharmaceutical Development and Technology Pub Date : 2025-11-01 Epub Date: 2025-11-06 DOI: 10.1080/10837450.2025.2579559

Ibtihal Abuhamdeh, Kamal Sweidan, Rania Hamed

{"title":"Carvedilol microemulsion-loaded oleogel for oral delivery: investigation of in vitro drug release and evaluation of chemical and physical stability.","authors":"Ibtihal Abuhamdeh, Kamal Sweidan, Rania Hamed","doi":"10.1080/10837450.2025.2579559","DOIUrl":"10.1080/10837450.2025.2579559","url":null,"abstract":"A semisolid oral formulation of carvedilol microemulsion-loaded oleogel (CARV-MEOG), filled in hard gelatin capsules, was developed and investigated for in vitro dissolution at different physiological pH levels. In vitro dissolution studies were conducted on CARV-MEOG and the reference product, Coreg® CR, in dissolution media that simulate the gastrointestinal fluid and cover its physiological pH range. The stability of CARV-MEOG was assessed both chemically and physically. Results showed that CARV formed intermolecular forces with oleic acid, the oil phase of the microemulsion, through the N-H bond of CARV, which disappeared in the CARV and oleic acid mixture. In 0.1 M HCl dissolution medium, CARV release attained 102.5 ± 2.66% after 24 h. In pH 4.5, 6.8, and 7.5 dissolution media, CARV release was significantly lower, achieving 65.6 ± 2.73%, 20.1 ± 1.32%, and 26.3 ± 1.67%, respectively, after 24 h. Compared to Coreg® CR, the release of CARV after 24 h was lower than that from CARV-MEOG, attaining 91.2 ± 1.03%, comparable to CARV-MEOG in pH 4.5, where it reached 76.8 ± 1.32%, and it was higher than CARV-MEOG in pH 6.8 and 7.5, attaining 59.0 ± 0.88% and 54.2 ± 1.01%, respectively. CARV-MEOG remained stable for 6 months when stored at 5-8 °C. Therefore, the development of CARV-MEOG successfully enhanced the dissolution rate of the poorly soluble drug carvedilol, aiming to improve its oral bioavailability.","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1320-1337"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transdermal drug delivery systems for psychological disorders. 心理障碍的经皮给药系统。

IF 2.5 4区医学

Pharmaceutical Development and Technology Pub Date : 2025-11-01 Epub Date: 2025-11-03 DOI: 10.1080/10837450.2025.2576778

Seyed Mohammad Iman Moezzi, Sara Masoumi Shahrbabak, Sogand Amiri, Sajjad Hajihosseini, Reyhane Masoudifar, Ehsan MostafaNejadian, Hamid Akbari Javar

{"title":"Transdermal drug delivery systems for psychological disorders.","authors":"Seyed Mohammad Iman Moezzi, Sara Masoumi Shahrbabak, Sogand Amiri, Sajjad Hajihosseini, Reyhane Masoudifar, Ehsan MostafaNejadian, Hamid Akbari Javar","doi":"10.1080/10837450.2025.2576778","DOIUrl":"10.1080/10837450.2025.2576778","url":null,"abstract":"The rapid growth in the number of patients with psychological disorders puts immense pressure on the economy, society, and healthcare systems. Various classes of drugs have been approved for different psychological disorders; however, a vast number of these medicines experience first-pass metabolism and low bioavailability, plasma level fluctuations, side effects, and the need for frequent daily doses, which all lead to poor patient compliance. Besides, the mental condition of these patients makes it hard for them to use drugs in oral dosage forms, frequently. Transdermal delivery systems have drawn attention to the treatment of different psychological disorders, including psychosis, depression, anxiety, attention-deficit hyperactivity disorder (ADHD), and sleep disorders. These systems offer a substitute route to address mentioned issues and improve patient adherence, particularly in long-term administration. Different devices have been designed to facilitate the administration of drugs through transdermal routes, such as patches and microneedles. Moreover, to enhance the absorption of medicines, chemical penetration enhancers, iontophoresis, radiofrequency, and nanotechnology are integrated with these transdermal delivery systems, which is the basis of the development of generations of transdermal delivery systems. In this review, we will focus on more novel generations of transdermal delivery systems and their applications for psychological disorders.","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1413-1448"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145401554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stability assessment of a novel 3D-printed oral dosage form of Mexiletine Hydrochloride: a six-month shelf-life study. 新型3d打印口服盐酸美西汀剂型的稳定性评估：六个月的保质期研究。

IF 2.5 4区医学

Pharmaceutical Development and Technology Pub Date : 2025-11-01 Epub Date: 2025-11-16 DOI: 10.1080/10837450.2025.2590122

Anouar Ait Hoummad, Arwin Ramcharan, Fereshteh Shokri

{"title":"Stability assessment of a novel 3D-printed oral dosage form of Mexiletine Hydrochloride: a six-month shelf-life study.","authors":"Anouar Ait Hoummad, Arwin Ramcharan, Fereshteh Shokri","doi":"10.1080/10837450.2025.2590122","DOIUrl":"10.1080/10837450.2025.2590122","url":null,"abstract":"This study presents the first evaluation of the shelf life of a novel three-dimensional (3D) printed formulation of Mexiletine Hydrochloride (HCl) over a six-month storage period. Mexiletine HCl was incorporated into a patient-personalized solid oral dosage form using a Semi-Solid Extrusion (SSE) 3D printing technique, and was then subjected to a preliminary stability assessment. We evaluated physical and chemical stability under ICH-recommended storage conditions, taking an important first step toward future full ICH-compliant studies. 3D-printed tablets were stored in a climatic cabinet, at 25 ± 2 °C and relative humidity 60 ± 5% (RH). The tablets were then evaluated for drug content analysis and impurities at 0 and 6 months of storage. Throughout the evaluation period, the printed tablets retained their physical characteristics, including shape and color, and exhibited no significant deviation in drug content and weight. Moreover, no detectable levels of degradation products or impurities were observed, as confirmed by validated analytical methods. These findings collectively indicate that the 3D-printed Mexiletine HCl formulation demonstrates excellent stability under room temperature storage conditions-information that is essential for advancing the formulation along regulatory and commercial pathways. Our data address the common trade-off between printability and stability, demonstrating that a formulation optimized for SSE printing can maintain stability under standard storage conditions.","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1525-1534"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Praeruptorin A-loaded MIL-100(Fe) dry powder inhalant for chronic pulmonary inflammatory diseases therapy. 含MIL-100（Fe）干粉吸入剂治疗慢性肺部炎性疾病。

IF 2.5 4区医学

Pharmaceutical Development and Technology Pub Date : 2025-11-01 Epub Date: 2025-11-30 DOI: 10.1080/10837450.2025.2594028

Houyuan Yang, Shuoying Liu, Tingyu Ge, Qian Wang, Mengqi Li, Chenglin Shu, Wei Fang, Ying Li, Dianlei Wang

{"title":"Praeruptorin A-loaded MIL-100(Fe) dry powder inhalant for chronic pulmonary inflammatory diseases therapy.","authors":"Houyuan Yang, Shuoying Liu, Tingyu Ge, Qian Wang, Mengqi Li, Chenglin Shu, Wei Fang, Ying Li, Dianlei Wang","doi":"10.1080/10837450.2025.2594028","DOIUrl":"10.1080/10837450.2025.2594028","url":null,"abstract":"Peucedanum praeruptorum Dunn has long been used in traditional Chinese medicine (TCM) for the treatment of respiratory diseases, its active constituent praeruptorin A (PA) has multiple anti-inflammatory activities. However, its bioavailability and therapeutic effect is not satisfactory in clinic owing to many physicochemical and physiologic barriers. Herein, this work highlights the successful development of an inhalable PA dry powder (MIL-100(Fe)-PA), which is facilely constructed through the optimization of the formulation between PA and a metal-organic framework (MIL-100(Fe)) carrier. Moderate pore and particle size distribution endow the dry powder with excellent loading efficiency and resistance to degradation. All ingredients and their interactions endow MIL-100(Fe)-PA favorable flowability, and pulmonary deposition, as well as direct lung drug delivery and release. These attractive characteristics enable the dry powder to effectively enhance alveolar epithelial cell penetration, improve anti-inflammatory activity, promote lung accumulation, and reduce the side effects of PA. Thus, this PA dry powder may open a new avenue for the inhalation treatment of diseases, greatly advancing its clinical application.","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1596-1608"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145582463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preliminary assessment of repurposed mebendazole nano-systems for passive targeting and potential treatment of bone metastasis. 重组甲苯达唑纳米系统被动靶向治疗骨转移的初步评估。

IF 2.5 4区医学

Pharmaceutical Development and Technology Pub Date : 2025-11-01 Epub Date: 2025-10-16 DOI: 10.1080/10837450.2025.2574082

Nouran M Atia, Ossama Y Abdallah, Heba A Hazzah, Rania G Aly, Hamdy Abdelkader, Adel Al Fatease, Raid G Alany, Hebatallah S Barakat

{"title":"Preliminary assessment of repurposed mebendazole nano-systems for passive targeting and potential treatment of bone metastasis.","authors":"Nouran M Atia, Ossama Y Abdallah, Heba A Hazzah, Rania G Aly, Hamdy Abdelkader, Adel Al Fatease, Raid G Alany, Hebatallah S Barakat","doi":"10.1080/10837450.2025.2574082","DOIUrl":"10.1080/10837450.2025.2574082","url":null,"abstract":"Bone metastasis is commonly observed in cancer patients, necessitating high-dose chemotherapy for effective treatment. Repurposing mebendazole (Meb) has shown promise in inhibiting cancer progression. To overcome its poor solubility and enhance tumor targeting, nanocrystals were employed as a delivery platform. The current work aimed to develop optimized Meb nanocrystals with improved bone metastasis therapeutic potential via passive targeting. Optimization was achieved through high shear homogenization and stabilizer selection (HPMC E15) to produce nanocrystals with enhanced colloidal stability and size uniformity. In vitro characterization and in-vivo assessment were conducted to compare the selected optimized formulation with the Meb solution. Two Meb nanocrystal formulations, homogenized (NC4) and unhomogenized (NC*), were compared to determine the importance of particle size reduction. The results revealed that NC4, prepared using anti-solvent precipitation combined with high shear homogenization, exhibited a promising particle size (121.20 ± 6.20 nm) and higher drug release in the acidic pH, favorable for passive targeting. The in vivo results confirmed the superior effects on tumor growth inhibition (90.01%), pain remission, and bone tumor markers of NC4 over NC*. NC4 showed an absence of kidney and liver toxicity. In conclusion, these comprehensive findings strongly support the clinical relevance of NC4 in treating bone metastasis. Its ability to passively target the drug, inhibit tumor growth, alleviate pain, and exhibit favorable biomarker profiles and safety make it a promising candidate for improving the management and outcomes of patients with bone metastasis.","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1285-1305"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145286702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preparation of Rhein-loaded hyaluolimosomes as a topical nanocarrier for melanoma: physicochemical characterization, ex-vivo permeation and human melanoma cell line studies, A375. 大黄酸透明质粒作为黑色素瘤局部纳米载体的制备：理化特性、体外渗透和人类黑色素瘤细胞系研究，A375。

IF 2.5 4区医学

Pharmaceutical Development and Technology Pub Date : 2025-11-01 Epub Date: 2025-11-11 DOI: 10.1080/10837450.2025.2580490

Mahmoud M A Ismail, Ossama Y Abdallah, Marwa M Essawy, Yosra S R Elnaggar

{"title":"Preparation of Rhein-loaded hyaluolimosomes as a topical nanocarrier for melanoma: physicochemical characterization, ex-vivo permeation and human melanoma cell line studies, A375.","authors":"Mahmoud M A Ismail, Ossama Y Abdallah, Marwa M Essawy, Yosra S R Elnaggar","doi":"10.1080/10837450.2025.2580490","DOIUrl":"10.1080/10837450.2025.2580490","url":null,"abstract":"Rhein (RH) is a promising phytochemical with well-documented pharmacological effects in several types of cancer. However, its pharmacological activity in skin cancer has not been studied. Moreover, RH suffers from numerous limitations that handicap its clinical applications, such as its poor aqueous solubility and dermal bioavailability. Herein, this study highlights, for the first time, RH application on skin cancer human melanoma cell line A375 and determines its IC50, the development of a novel rhein-loaded transferosomes; hyaluolimosomes, and its evaluation as a free drug and nano-drug. The formation of the RH-PL complex (RH-PLC) was verified by infrared spectroscopy, thermal analysis via differential scanning calorimetry, and structural examination through X-ray powder diffraction. Studies on in-vitro release and ex-vivo permeation and skin deposition showed the superiority of hyaluolimosomes to significantly improve RH release, skin permeation, and deposition compared with the free drug. Cell viability studies on A375 revealed a significant reduction in IC50 of hyaluolimosomes at 31.3 µg/mL compared to 434.8 µg/mL of rhein (12.89 fold) with safety profiles. The present study successfully achieved its primary objective by demonstrating cytotoxic activity against the melanoma cell line. On the other hand, an important issue of concurrent cytotoxicity was observed on HDFa cells, highlighting the need for incorporating active targeting strategies in future preclinical investigations.","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1359-1371"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145378326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polymeric nanogels loaded with Eugenia uniflora L. dry extract: the role of span^® 80 in rheology, release, and skin permeation. 聚合纳米凝胶装载Eugenia uniflora L.干提取物：Span®80在流变学，释放和皮肤渗透中的作用。

IF 2.5 4区医学

Pharmaceutical Development and Technology Pub Date : 2025-11-01 Epub Date: 2025-11-06 DOI: 10.1080/10837450.2025.2584118

Leandro Leal Kloppel, Bruno Dos Santos Souza, Gabriella Alves, Rayssa Barbary Pedroza Moura, Mônica Freiman de S Ramos, Antonio Carlos Siani, Ricardo Neves Marreto, Stephânia Fleury Taveira

{"title":"Polymeric nanogels loaded with Eugenia uniflora L. dry extract: the role of span® 80 in rheology, release, and skin permeation.","authors":"Leandro Leal Kloppel, Bruno Dos Santos Souza, Gabriella Alves, Rayssa Barbary Pedroza Moura, Mônica Freiman de S Ramos, Antonio Carlos Siani, Ricardo Neves Marreto, Stephânia Fleury Taveira","doi":"10.1080/10837450.2025.2584118","DOIUrl":"10.1080/10837450.2025.2584118","url":null,"abstract":"Fungal skin infections remain a global health concern, and current topical treatments often present limitations in efficacy and skin permeation, highlighting the need for innovative actives and delivery systems. Eugenia uniflora L. (EU) has demonstrated antifungal activity. Therefore, this study aimed to develop and characterize nanogels containing poloxamers and Span 80 for the topical delivery of EU dry extract (DryExt). An analytical method was developed, and formulations were obtained with 3, 6, and 12% of Span 80 (PS3%, PS6%, and PS12%, respectively) with DryExt. The formulations were fully characterized, and rheological, in vitro release, permeation, and irritation potential studies were performed. The formulations had nanometric diameters (200-400 nm), spherical, with a dark and thick halo, suggesting vesicle formation. With increasing Span 80 concentration, the viscosity of the formulations increased, and the sol-gel transition temperature decreased. Span 80 also enhanced the release and permeation of DryExt markers (ellagic acid - EA, gallic acid - GA, myricitrin - MYR). For instance, compared with PS3%-DryExt, PS12%-DryExt enhanced GA and MYR skin permeation by up to 5-fold. No irritation was observed. In conclusion, adding Span to the formulation benefits skin permeation and viscosity, supporting its potential as an effective topical antifungal delivery system.","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1372-1388"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145438787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The functional attributes of co-processed excipients in direct compression. 直接压缩中共加工辅料的功能属性。

IF 2.5 4区医学

Pharmaceutical Development and Technology Pub Date : 2025-11-01 Epub Date: 2025-11-10 DOI: 10.1080/10837450.2025.2584127

Renate Coetzee, Josias Hamman, Jan Steenekamp, Hannlie Hamman

{"title":"The functional attributes of co-processed excipients in direct compression.","authors":"Renate Coetzee, Josias Hamman, Jan Steenekamp, Hannlie Hamman","doi":"10.1080/10837450.2025.2584127","DOIUrl":"10.1080/10837450.2025.2584127","url":null,"abstract":"The pharmaceutical industry is increasingly adopting co-processed excipients as alternatives to conventional excipients in tablet manufacturing despite certain regulatory challenges. Co-processing of excipients was designed to optimize physical powder properties such as flowability, compressibility, and compactibility, which are critical attributes for efficient tablet production, especially by means of direct compression. This review summarizes the various preparation methods of co-processed excipients and comprehensively discusses the role of co-processed excipients over conventional pharmaceutical excipients in enhancing tablet formulation as well as tablet manufacturing efficiency and consistency due to their improved functionality. Furthermore, the functionality and enhancement of performance of co-processed excipients are discussed on the three levels of solid substances, namely the molecular, particle and bulk levels. It further evaluates the effectiveness of co-processed excipients in addressing common formulation challenges such as moisture, lubricant sensitivity and strain rate sensitivity.","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1389-1412"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia. 模拟乳糜微粒的超分子纳米乳用于口服木犀草素治疗高尿酸血症。

IF 2.5 4区医学

Pharmaceutical Development and Technology Pub Date : 2025-11-01 Epub Date: 2025-11-26 DOI: 10.1080/10837450.2025.2591746

Miao Wang, Linlin Zhao, Yujiao Liu, Deyong Tian, Aijiao Jiang, Qianqi Cai, Yucheng Xiang, Lie Zhang, Yan Chen, Jing Ye, Aikebaier Reheman, Quan Zhang

{"title":"Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia.","authors":"Miao Wang, Linlin Zhao, Yujiao Liu, Deyong Tian, Aijiao Jiang, Qianqi Cai, Yucheng Xiang, Lie Zhang, Yan Chen, Jing Ye, Aikebaier Reheman, Quan Zhang","doi":"10.1080/10837450.2025.2591746","DOIUrl":"10.1080/10837450.2025.2591746","url":null,"abstract":"Hyperuricemia, a prevalent metabolic disorder, severely impacts life quality. Luteolin (LUT), a natural flavonoid compound, demonstrates potential anti-hyperuricemic effects along with a high safety profile. However, its clinical application is greatly limited by poor oral bioavailability, mainly due to low permeability and inadequate gastrointestinal stability. To address this, we developed a chylomicron-mimicking supramolecular nanoemulsion (LUT-CMSN) composed of soybean oil and a supramolecular aggregate formed between LUT and Kolliphor® HS 15 (HS 15). LUT-CMSN exhibited a near-spherical morphology with an average particle size of approximately 14.2 nm. With CMSN encapsulation, LUT exhibited notably improved permeability and stability in the gastrointestinal tract. After oral administration, LUT-CMSN could be absorbed by lymphatic transport into blood circulation, consequently achieving 4.63-fold higher Cmax and 2.59-fold greater AUC(0-t) compared with free LUT. Additionally, LUT-CMSN showed markedly enhanced distribution in the liver and kidney relative to free LUT. In the acute and chronic hyperuricemia animal model, LUT-CMSN effectively reduced serum uric acid levels through inhibition of xanthine oxidase (XOD) activity and observably alleviated the renal injury induced by hyperuricemia. Taken together, LUT-CMSN represents a promising oral delivery platform for enhancing the bioavailability of LUT and a potential therapeutic strategy for the treatment of hyperuricemia.","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1543-1556"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145550216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction statement. 撤销声明。

IF 2.5 4区医学

Pharmaceutical Development and Technology Pub Date : 2025-11-01 Epub Date: 2025-10-30 DOI: 10.1080/10837450.2025.2580799

引用次数: 0